Regulatory Roundup: FDA Announced Upcoming Part 11 Inspections; And More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: FDA Announced Upcoming Part 11 Inspections; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration announced last week that it will be “conducting a series of inspections in an effort to evaluate industry’s compliance and understanding of [21 CFR] Part 11.” The agency intends to take appropriate action to enforce Part 11 requirements for issues raised during the inspections that do not fall under the enforcement discretion discussed in the 2003 Guidance for Industry: Part 11, Electronic Records; Electronic Signatures—Scope and Application. (See related blog post.)

   
FDA also issued a new Guidance for Industry: Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions, Annex 13. This particular annex harmonizes the analytical procedures used for bulk density and tapped density of powders across the US, Europe, and Japan. ICH adopted Annex 13 in June 2010. FDA has published other harmonized Q4B annexes as guidance’s over the past year, including Annex 5 Disintegration Test, 7 Dissolution Test, 8 Sterility Test, 9 Tablet Friability, and 10 Polyacrylamide Gel Electrophoreses.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here